Review of Patient Gene Profiles Obtained through a Non-Negative Matrix Factorization-Based Framework to Determine the Role Inflammation Plays in Neuroblastoma Pathogenesis

Author:

Boccarelli Angelina1ORCID,Del Buono Nicoletta2ORCID,Esposito Flavia2ORCID

Affiliation:

1. Department of Precision and Regenerative Medicine and Polo Jonico, School of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70121 Bari, Italy

2. Department of Mathematics, University of Bari Aldo Moro, Via Edoardo Orabona 4, 70125 Bari, Italy

Abstract

Neuroblastoma is the most common extracranial solid tumor in children. It is a highly heterogeneous tumor consisting of different subcellular types and genetic abnormalities. Literature data confirm the biological and clinical complexity of this cancer, which requires a wider availability of gene targets for the implementation of personalized therapy. This paper presents a study of neuroblastoma samples from primary tumors of untreated patients. The focus of this analysis is to evaluate the impact that the inflammatory process may have on the pathogenesis of neuroblastoma. Eighty-eight gene profiles were selected and analyzed using a non-negative matrix factorization framework to extract a subset of genes relevant to the identification of an inflammatory phenotype, whose targets (PIK3CG, NFATC2, PIK3R2, VAV1, RAC2, COL6A2, COL6A3, COL12A1, COL14A1, ITGAL, ITGB7, FOS, PTGS2, PTPRC, ITPR3) allow further investigation. Based on the genetic signals automatically derived from the data used, neuroblastoma could be classified according to stage rather than as a “cold” or “poorly immunogenic” tumor.

Funder

Piano Nazionale di Ripresa e Resilienza (PNRR), Missione 4 “Istruzione e Ricerca”—Componente C2 Investimento 1.1

Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale

Publisher

MDPI AG

Reference54 articles.

1. Neuroblastoma: Paradigm for precision medicine;Irwin;Pediatr. Clin. N. Am.,2015

2. Neuroblastoma Origin and Therapeutic Targets for Immunotherapy;Kholodenko;J. Immunol. Res.,2018

3. Immune checkpoint molecules in neuroblastoma: A clinical perspective;Pathania;Semin. Cancer Biol.,2022

4. Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies;Lundberg;Curr. Onc. Rep.,2022

5. Cancer stem cells in neuroblastoma therapy resistance;Aravindan;Cancer Drug Resist.,2019

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3